Thompson Sees Huge Influx of New Refractive Tech

Vance Thompson, MD is an internationally recognized specialist in Laser Vision Correction and Advanced Cataract Surgery. As a leading international researcher he has played a key role in the development of the most advanced technologies and techniques for both laser and implant vision correction. Dr. Thompson led our Refractive Correction – Corneal & Intraocular Breakfast…

Read More

Encore Vision Reports Positive Phase I/II Results

Results from a Phase I/Phase II study of EV06 ophthalmic solution for the treatment of presbyopia show “it works to restore bilateral near vision. It is safe and well-tolerated,” said president and CEO Bill Burns. Encore Vision has just come off a round of successful capital financing that should see it through the next phase…

Read More

ReVision Optics Eyes Panel Discussion in Q3

The Raindrop Near Vision Inlay for the treatment of presbyopia boasts a 2-mm diameter, 80% water composition, the same refractive index as the natural cornea, and is removable, said ReVision Optics’ president and CEO John Kilcoyne. “This is profocal shape-changing technology,” he said. “The Raindrop changes the anterior curvature of cornea to improve near and…

Read More

Allotex

OIS@ASCRS - Companies to Watch - Allotex 2016

The driving force behind Allotex was the observation that the potential interest in synthetic corneal inlay technology was being dampened by the persistent biocompatibility issue. Recognizing the many technological changes that have occurred since Barraquer’s early pioneering epikeratophakia work, the company was established to develop human allograft inlays and onlays to satisfy a growing market…

Read More

Lindstrom Eyes Improvements to Eye Drops

Richard Lindstrom, MD, led the OIS@ASRCS breakfast breakout session “Innovative Alternatives to Drops.” Hear his recap of the problem and the potential solutions that may someday help current and new medicines reach the areas of the eye that need them most. Video Highlights: 00:48 – If everyone used their eye drops they’d be quite safe…

Read More

Eye on Five – April Edition

OIS - Eye on Five

FDA Approves Avedro Corneal Collagen Cross-linking Platform The US Food and Drug Administration finally gave a green light to Avedro Inc. for its KXL System, a corneal collagen cross-linking platform for the treatment of progressive keratoconus. An FDA joint panel recommended approval in February last year, but a month later the agency denied approval, asking…

Read More

Avedro Finally Secures FDA Approval

Avedro Finally Secures FDA Approval - Eye on Innovation Article

On Monday, Avedro Inc. announced the US Food and Drug Administration finally gave a green light for its KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus. This is a story we’ve been following at OIS.net. According to the company, keratoconus is a progressive thinning and distortion of the cornea. It is…

Read More

Avedro’s Long Wait for FDA Approval is Over

Avedro’s Long Wait for FDA Approval Is Over - OIS Podcast

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 082″] The FDA approved Avedro’s New Drug Application for its riboflavin ophthalmic solution/KXL System (corneal cross-linking for the treatment of keratoconus and corneal ectasia following refractive surgery). OIS Co-chair Gil Kliman, an investor in Avedro, lays out the company’s next plans. 10 Top Topics in this OIS Podcast: Can you give…

Read More

The OIS Lifetime Innovator Award goes to…

Roger Steinert, MD     For A Lifetime of Exceptional Contributions to Ophthalmic Innovation and Entrepreneurship Dr. Steinert’s advanced skill and excellent surgical results have earned him a reputation as an international consultant and leader in cataract surgery, refractive surgery and corneal transplants. He has conducted numerous, high-profile research studies and remains at the forefront…

Read More

2016 Promises to Disrupt Dry Eye

Drugs & Devices for Dry Eye - Ophthalmology Innovation Summit 2015

This year promises to deliver disruption to the dry eye disease market as companies work to roll out new drugs, devices, and diagnostics. Shire may deliver the biggest success. The company is close to bringing a second therapeutic to the market to treat dry eye conditions, as lifitegrast is currently awaiting US regulatory approval. If…

Read More

FDA Looking to Follow Up on Year of “Firsts”

OIS@AAO - Breakfast with the FDA

If you’re an executive at an ophthalmic drug development company and desire a frank discussion on regulatory issues that are critical to your business, you’d certainly jump at the chance to invite to breakfast Wiley Chambers, MD, deputy director of the Division of Transplant and Ophthalmology Products within FDA’s Center for Drug Evaluation and Research.…

Read More

Muller Explains Departure from Avedro; Opportunity in New Venture

OIS-Podcast

[creativ_pullleft colour=”light-gray” colour_custom=”” text=”Episode 071″] David Muller came close to writing the final chapter of Avedro’s push to have corneal cross-linking approved by the FDA. But he opted to leave the company before the final approval came through to pursue a new venture called Allotex. In this interview with OIS Podcast, Muller explains his decision…

Read More